TITLE

Zidovudine/Lamivudine for HIV-1 Infection Contributes to Limb Fat Loss

AUTHOR(S)
van Vonderen, Marit G. A.; van Agtmael, Michiel A.; Hassink, Elly A. M.; Milinkovic, Ana; Brinkman, Kees; Geerlings, Suzanne E.; Ristola, Matti; van Eeden, Arne; Danner, Sven A.; Reiss, Peter
PUB. DATE
May 2009
SOURCE
PLoS ONE;2009, Vol. 4 Issue 5, p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Lipoatrophy is known to be associated with stavudine as part of the treatment for HIV infection, but it is less clear if this serious side effect is also related to other nucleoside reverse transcriptase inhibitors like zidovudine. We aimed to determine whether zidovudine-sparing first-line antiretroviral therapy would lead to less lipoatrophy and other metabolic changes than zidovudine-containing therapy. Methodology/Principal Findings: Fifty antiretroviral therapy-naïve HIV-1 infected men with an indication to start antiretroviral therapy were included in a randomized single blinded clinical trial. Randomisation was between zidovudinecontaining therapy (zidovudine/lamivudine+lopinavir/ritonavir) and zidovudine-sparing therapy (nevirapine+lopinavir/ ritonavir). Main outcome measures were body composition assessed by computed tomography and dual-energy X-ray absorptiometry scan and lipid profile before and after 3, 12, 24 months of antiretroviral therapy. In the zidovudine/ lamivudine+lopinavir/ritonavir group, from 3 months onward limb fat decreased progressively by 6846293 grams (estimated mean6standard error of the mean)(p = 0.02) up to 24 months whereas abdominal fat increased, but exclusively in the visceral compartment (+21.9±8.1 cm2, p = 0.008)). In contrast, in the nevirapine+lopinavir/ritonavir group, a generalized increase in fat mass was observed. After 24 months no significant differences in high density lipoprotein and total/high density lipoprotein cholesterol ratio were found between both treatment groups, but total and low density lipoprotein cholesterol levels were higher in the nevirapine+lopinavir/ritonavir group (6.1±0.2 versus 5.3±0.2 and 3.6±0.1 versus 2.8±0.1 mmol/l respectively, p<0.05). Virologic response and safety were comparable in both groups. Conclusions/Significance: Zidovudine/lamivudine+lopinavir/ritonavir, but not nevirapine+lopinavir/ritonavir in antiretroviral therapy-naïve patients, is associated with lipoatrophy and greater relative intraabdominal lipohypertrophy, suggesting that zidovudine/lamivudine contributes to both these features of lipodystrophy. These findings support to no longer consider zidovudine/lamivudine as one of the preferred possible components of first-line antiretroviral therapy where alternative treatments are available.
ACCESSION #
55980083

 

Related Articles

  • Nucleoside Reverse Transcriptase Inhibitor Resistance Mutations Associated with First-Line Stavudine-Containing Antiretroviral Therapy: Programmatic Implications for Countries Phasing Out Stavudine. Tang, Michele W.; Rhee, Soo-Yon; Bertagnolio, Silvia; Ford, Nathan; Holmes, Susan; Sigaloff, Kim C.; Hamers, Raph L.; de Wit, Tobias F. Rinke; Fleury, Herve J.; Kanki, Phyllis J.; Ruxrungtham, Kiat; Hawkins, Claudia A.; Wallis, Carole L.; Stevens, Wendy; van Zyl, Gert U.; Manosuthi, Weerawat; Hosseinipour, Mina C.; Ngo-Giang-Huong, Nicole; Belec, Laurent; Peeters, Martine // Journal of Infectious Diseases;Jun2013, Vol. 207 Issue suppl_2, pS70 

    Background The World Health Organization Antiretroviral Treatment Guidelines recommend phasing-out stavudine because of its risk of long-term toxicity. There are two mutational pathways of stavudine resistance with different implications for zidovudine and tenofovir cross-resistance, the primary...

  • Etravirine: A Guide to Its Use in Treatment-Experienced Pediatric Patients with HIV-1 Infection in the US. Lyseng-Williamson, Katherine A. // Pediatric Drugs;2012, Vol. 14 Issue 5, p345 

    Etravirine (Intelence®), an oral next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI), is approved for the treatment of HIV-1 infection in treatment-experienced patients. In the US, the approved use of etravirine in patients who have evidence of viral replication and harbor...

  • Lamivudine monotherapy as a holding regimen in the era of antiretroviral treatment resistance. Meyer, J. C.; Schellack, N. B. // South African Pharmaceutical Journal;2015, Vol. 82 Issue 9, p43 

    Limited treatment options are available for HIV-infected paediatric patients that are virologically failing combination antiretroviral treatment (cART). This paper describes the use of lamivudine monotherapy (LM) as a holding strategy for the short-term treatment of specific multi-drug resistant...

  • Effect of Coadministration of Neurovite and Lamivudine on the Histomorphology of the Cerebellum of Wistar Rats. Peter, A. I.; Ekong, M. B.; Davies, K.; Azu, O. O.; Bassey, R. B.; Ugwu, L. O.; Umoh, I. U. // ISRN Otolaryngology;2014, p1 

    Introduction. Lamivudine is a nucleoside reverse transcriptase inhibitor antiretroviral agent used in the treatment of human immunodeficiency virus type 1 infection. This study was to investigate the effects of coadministration of neurovite and lamivudine on the histomorphology of the cerebellum...

  • CONTROLLED AND SUSTAINED RELEASE APPROACHES IN DEVELOPING SUITABLE DOSAGE FORMS FOR THE ANTIRETROVIRAL DRUG LAMIVUDINE. Vamshi Alla, Krishna; Praveen Kumar, Gannu; Cheruku, Vishvasa; Jannu, Anand; Kumari Bairi, Chaitanya // International Journal of Pharmaceutical Sciences Review & Resear;May/Jun2011, Vol. 8 Issue 1, p21 

    Lamivudine is a Nucleoside Reverse Transcriptase Inhibitor (NRTI), licensed for the treatment of HIV, and chronic Hepatitis B. The pharmacokinetic data of Lamivudine shows that, frequent administration for a prolonged period of time (lifelong in AIDS and for one year in hepatitis patients) is...

  • Assessing efficacy of different nucleos(t)ide backbones in NNRTI-containing regimens in the Swiss HIV Cohort Study. Wan-Lin Yang; Kouyos, Roger D.; Scherrer, Alexandra U.; Böni, Jürg; Shah, Cyril; Yerly, Sabine; Klimkait, Thomas; Aubert, Vincent; Hirzel, Cédric; Battegay, Manuel; Cavassini, Matthias; Bernasconi, Enos; Vernazza, Pietro; Held, Leonhard; Ledergerber, Bruno; Günthard, Huldrych F. // Journal of Antimicrobial Chemotherapy (JAC);Dec2015, Vol. 70 Issue 12, p3323 

    Background: The most recommended NRTI combinations as first-line antiretroviral treatment for HIV-1 infection in resource-rich settings are tenofovir/emtricitabine, abacavir/lamivudine, tenofovir/lamivudine and zidovudine/lamivudine. Efficacy studies of these combinations also considering pill...

  • Severe skin rash with lamivudine in HIV infected patients:Some unusual case reports. Modak, Dolanchampa; Guha, Subhasish Kamal // Indian Journal of Pharmacology;May/Jun2013, Vol. 45 Issue 3, p298 

    Lamivudine (3TC) is a nucleoside reverse transcriptase inhibitor (NRTI) licensed for as a first line drug in Human immunodeficiency virus (HIV) infection and also in the treatment of hepatitis B. It is relatively nontoxic in nature and potentiates the antiviral effects of other NRTIs like...

  • Mitochondrial toxicities of nucleoside analogue reverse transcriptase inhibitors in AIDS cases. Marfatia, Yogesh S.; Talwar, Mahima; Agrawal, Meetesh; Sharma, Ajay; Mehta, Kajal // Indian Journal of Sexually Transmitted Diseases;Jul-Dec2014, Vol. 35 Issue 2, p96 

    The development of antiretroviral therapy (ART) has been one of the most dramatic progressions in the history of medicine. Concomitant with this momentous therapeutic advance, the mitochondrial toxicities of ART were recognized as an important clinical entity. Aim: The aim was to study the...

  • Pharmacokinetics of Etravirine Combined with Atazanavir/Ritonavir and a Nucleoside Reverse Transcriptase Inhibitor in Antiretroviral Treatment-Experienced, HIV-1-Infected Patients. Orrell, Catherine; Felizarta, Franco; Nell, André; Kakuda, Thomas N.; Lavreys, Ludo; Nijs, Steven; Tambuyzer, Lotke; Van Solingen-Ristea, Rodica; Tomaka, Frank L. // AIDS Research & Treatment;1/15/2015, Vol. 2015, p1 

    Objectives. TEACH (NCT00896051) was a randomized, open-label, two-arm Phase II trial to investigate the pharmacokinetic interaction between etravirine and atazanavir/ritonavir and safety and efficacy in treatment-experienced, HIV-1-infected patients. Methods. After a two-week lead-in of two...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics